PRINT THIS PAGE Investing in life29/10/2003. Source: Asia Private Equity Review.
In the year ending June 2003 there were three substantial biotechnology funds raised in Asia, amounting to $50.5m. Although just a fragment of the industry's colossal $100bn global capital pool, this still represents a near three-fold increase on the previous year, according to the Asia Private Equity Review. Japan and Taiwan have traditionally been seen as the most fertile ground for biotech funds in Asia. But the $325m raised by Asian biotech funds in the last four years has, in fact, been spread among six Asian markets.
Click here to view full report (pdf 320kb)
You need Adobe Acrobat to read this document. If you do not have it, you can download it free from www.adobe.com/products/acrobat/readstep.html
Asia Private Equity Review (APER) is the foremost voice on matters related to private equity/venture capital in the region. Well-recognised as being the singular source for accurate and timely news, in-depth analysis and global perspectives, APER is published by the Hong Kong-based Centre for Asia Private Equity Research. For further information please visit our website at www.asiape.com or email us at info@asiape.com.
.
|
